Comparing Bio-Techne (NASDAQ:TECH) & Artiva Biotherapeutics (NASDAQ:ARTV)

Bio-Techne (NASDAQ:TECH) and Artiva Biotherapeutics (NASDAQ:ARTV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Bio-Techne and Artiva Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Techne	13.22%	12.73%	9.75%
Artiva Biotherapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Bio-Techne and Artiva Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.21 billion	6.39	$168.10 million	$0.82	60.10
Artiva Biotherapeutics	$251,000.00	196.07	N/A	N/A	N/A

Bio-Techne has higher revenue and earnings than Artiva Biotherapeutics.

Institutional & Insider Ownership

98.9% of Bio-Techne shares are owned by institutional investors. 3.9% of Bio-Techne shares are owned by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bio-Techne and Artiva Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0	6	4	0	2.40
Artiva Biotherapeutics	0	0	6	0	3.00

Bio-Techne presently has a consensus price target of $73.44, suggesting a potential upside of 49.03%. Artiva Biotherapeutics has a consensus price target of $19.40, suggesting a potential upside of 860.40%. Given Artiva Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Bio-Techne.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.